effects of the combined treatment of the passiflora and the chamomile powder on the symptoms of depression and anxiety in postmenopausal women

Investigating the effects of the combined treatment of the passiflora and the chamomile powder on the symptoms of depression and anxiety in postmenopausal women

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20241009063310N1

Enrollment

Registered

2025-02-02

Start date

2024-09-22

Completion date

Unknown

Last updated

2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression and anxiety in postmenopausal women.

Interventions

Intervention 1: Intervention group: People in this group take one capsule of medicine daily for 60 days. The size 00 capsule contains one gram of a mixture of equal proportions of Passifloraceae and C

Eligibility

Sex/Gender

Female

Age

42 Years to 52 Years

Inclusion criteria

Inclusion criteria: postmenopausal women with depression and anxiety Their serum FSH level is less than 40 IU/L

Exclusion criteria

Exclusion criteria: Postmenopausal women who are younger than 42 years old. Postmenopausal women over 52 years old. Postmenopausal women who have had their menstrual periods stopped for less than twelve months.

Design outcomes

Primary

Measure	Time frame
Primary outcome: The final score on the 21-item Depression, Anxiety, and Stress Questionnaire. Timepoint: before the start of the intervention (at the beginning) and 60 days after the intervention. Method of measurement: The 21-item Depression, Anxiety, and Stress Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKataneh Abrari

Kharazmi University

k.abrari@khu.ac.ir+98 26 3457 9600

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026